PMID- 23773231
OWN - NLM
STAT- MEDLINE
DCOM- 20140515
LR  - 20220409
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 18
IP  - 6
DP  - 2013 Dec
TI  - Trends of second-line eradication therapy for Helicobacter pylori in Japan: a 
      multicenter study in the Tokyo metropolitan area.
PG  - 468-72
LID - 10.1111/hel.12063 [doi]
AB  - BACKGROUND: In Japan, the eradication rate of first-line therapy for Helicobacter 
      pylori (H. pylori) with a proton pump inhibitor (PPI), amoxicillin (AMPC) and 
      clarithromycin (CAM) has been decreasing because of a high prevalence of CAM 
      resistance. A possible decrease of the eradication rate for second-line therapy 
      with a PPI, AMPC and metronidazole (MNZ) is of concern. The aim of this study is 
      to assess the trends in second-line eradication therapy for H. pylori in Japan. 
      MATERIALS AND METHODS: We accumulated data retrospectively on patients 
      administered second-line eradication therapy for Helicobacter pylori with a PPI, 
      AMPC, and MNZ for 1 week after failure of first-line eradication therapy with a 
      PPI, AMPC and CAM at 15 facilities in the Tokyo metropolitan area in Japan from 
      2007 to 2011. Trends for second-line eradication rates in modified 
      intention-to-treat (ITT) analyses were investigated. Second-line eradication 
      rates were categorized by three PPIs (rabeprazole (RPZ), lansoprazole (LPZ) or 
      omeprazole (OMZ)) and evaluated. RESULTS: We accumulated data on 1373 patients. 
      The overall second-line eradication rate was 92.4%. Second-line eradication rates 
      in 2007, 2008, 2009, 2010 and 2011 were 97.7, 90.6, 94.5, 91.8 and 91.8%, 
      respectively, with no significant trends revealed. Second-line eradication rates 
      categorized by three PPIs for the entire 5-year period were 91.6, 93.4 and 92.4% 
      (RPZ, LPZ and OPZ, respectively) with no significant differences among the three 
      PPIs. CONCLUSIONS: From 2007 to 2011, there were no significant trends in the 
      second-line eradication rates and the rates remained consistently high. From the 
      viewpoint of high prevalence of CAM resistance in Japan, triple therapy with PPI, 
      AMPC and MNZ may be a better strategy for first-line therapy compared to triple 
      therapy with PPI, AMPC and CAM.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - Asaoka, Daisuke
AU  - Asaoka D
AD  - Tokyo HP Study Group, Department of Gastroenterology, Juntendo University School 
      of Medicine, Tokyo, Japan.
FAU - Nagahara, Akihito
AU  - Nagahara A
FAU - Matsuhisa, Takeshi
AU  - Matsuhisa T
FAU - Takahashi, Shin-Ichi
AU  - Takahashi S
FAU - Tokunaga, Kengo
AU  - Tokunaga K
FAU - Kawai, Takashi
AU  - Kawai T
FAU - Kawakami, Kohei
AU  - Kawakami K
FAU - Suzuki, Hidekazu
AU  - Suzuki H
FAU - Suzuki, Masayuki
AU  - Suzuki M
FAU - Nishizawa, Toshihiro
AU  - Nishizawa T
FAU - Kurihara, Naoto
AU  - Kurihara N
FAU - Ito, Masayoshi
AU  - Ito M
FAU - Sasaki, Hitoshi
AU  - Sasaki H
FAU - Omata, Fumio
AU  - Omata F
FAU - Mizuno, Shigeaki
AU  - Mizuno S
FAU - Torii, Akira
AU  - Torii A
FAU - Ohkusa, Toshifumi
AU  - Ohkusa T
FAU - Mine, Tetsuya
AU  - Mine T
FAU - Sakaki, Nobuhiro
AU  - Sakaki N
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20130618
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Anti-Bacterial Agents)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 140QMO216E (Metronidazole)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Clarithromycin/therapeutic use
MH  - *Disease Eradication
MH  - Drug Therapy, Combination
MH  - Female
MH  - Helicobacter Infections/*drug therapy/epidemiology/microbiology/prevention & 
      control
MH  - Helicobacter pylori/*drug effects/physiology
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Metronidazole/therapeutic use
MH  - Middle Aged
MH  - Omeprazole/therapeutic use
MH  - Retrospective Studies
MH  - Tokyo/epidemiology
MH  - Young Adult
OTO - NOTNLM
OT  - 7-day triple therapy
OT  - Helicobacter pylori
OT  - Second-line therapy
OT  - metonidazole
OT  - proton pump inhibitor
EDAT- 2013/06/19 06:00
MHDA- 2014/05/16 06:00
CRDT- 2013/06/19 06:00
PHST- 2013/06/19 06:00 [entrez]
PHST- 2013/06/19 06:00 [pubmed]
PHST- 2014/05/16 06:00 [medline]
AID - 10.1111/hel.12063 [doi]
PST - ppublish
SO  - Helicobacter. 2013 Dec;18(6):468-72. doi: 10.1111/hel.12063. Epub 2013 Jun 18.